563 related articles for article (PubMed ID: 24107103)
1. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
[TBL] [Abstract][Full Text] [Related]
2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
3. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
[TBL] [Abstract][Full Text] [Related]
4. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
6. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.
Legry V; Van Rooyen DM; Lambert B; Sempoux C; Poekes L; Español-Suñer R; Molendi-Coste O; Horsmans Y; Farrell GC; Leclercq IA
Clin Sci (Lond); 2014 Oct; 127(7):507-18. PubMed ID: 24766485
[TBL] [Abstract][Full Text] [Related]
8. Differential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding.
Jovicic N; Jeftic I; Jovanovic I; Radosavljevic G; Arsenijevic N; Lukic ML; Pejnovic N
PLoS One; 2015; 10(7):e0134089. PubMed ID: 26218873
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
[TBL] [Abstract][Full Text] [Related]
11. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice.
Arsov T; Larter CZ; Nolan CJ; Petrovsky N; Goodnow CC; Teoh NC; Yeh MM; Farrell GC
Biochem Biophys Res Commun; 2006 Apr; 342(4):1152-9. PubMed ID: 16516152
[TBL] [Abstract][Full Text] [Related]
12. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis.
Van Rooyen DM; Larter CZ; Haigh WG; Yeh MM; Ioannou G; Kuver R; Lee SP; Teoh NC; Farrell GC
Gastroenterology; 2011 Oct; 141(4):1393-403, 1403.e1-5. PubMed ID: 21703998
[TBL] [Abstract][Full Text] [Related]
13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
14. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
15. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
18. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.
Teoh NC; Williams J; Hartley J; Yu J; McCuskey RS; Farrell GC
Hepatology; 2010 Mar; 51(3):996-1006. PubMed ID: 20131406
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
20. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
